60 Degrees Pharmaceuticals, Inc. (SXTP)
- Previous Close
0.2160 - Open
0.2104 - Bid --
- Ask --
- Day's Range
0.2102 - 0.2300 - 52 Week Range
0.2010 - 8.6500 - Volume
70,464 - Avg. Volume
203,629 - Market Cap (intraday)
2.546M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.30
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
www.60degreespharma.comRecent News: SXTP
Performance Overview: SXTP
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SXTP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SXTP
Valuation Measures
Market Cap
2.55M
Enterprise Value
10.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.44
Price/Book (mrq)
--
Enterprise Value/Revenue
41.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-70.95%
Return on Equity (ttm)
--
Revenue (ttm)
253.57k
Net Income Avi to Common (ttm)
-3.77M
Diluted EPS (ttm)
-0.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.14M
Total Debt/Equity (mrq)
3.60%
Levered Free Cash Flow (ttm)
-6.22M
Research Analysis: SXTP
Company Insights: SXTP
SXTP does not have Company Insights